частое кровотечение из носа у ребенка 10 лет причины
Главное меню:
Интересное
частое кровотечение из носа у ребенка 10 лет причины, Semaglutide Attenuates Anxious and Depressive-Like Behaviors and , Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the , The Discovery and Development of Liraglutide and Semaglutide - ALZFORUM, NT-0796 | ALZFORUM, Semaglutide ameliorates cognition and glucose metabolism - ALZFORUM, Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its , Semaglutide as a possible therapy for healthy aging: Targeting the .
From August 2021 to August 2022, NodThera ran a Phase 1 first-in-human study to assess safety and pharmacokinetics of NT-0796 in 76 healthy volunteers. Single ascending doses from 1 to 300 mg were given as a liquid formulation. Multiple MAD cohorts were planned based on results of the single-dose study, and included CSF sampling. Pharmacodynamic outcomes included inflammatory cytokines IL-1β, IL-18, IL-6, and TNFα in serum, and after ex vivo stimulation of blood cells from participants. In May 2022, the company reported the drug was safe after single dosing, and showed dose-proportional pharmacokinetics. Treatment lowered inflammatory cytokine levels in the ex vivo blood cell assay (). A September 2022 on the multiple-dose part of the study claimed brain penetration to levels higher than needed to achieve an anti-inflammatory effect, and a reduction in blood levels of the inflammatory biomarker C-reactive protein after treatment. No doses were specified, or data shown., Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis., Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9 (1):157-171..
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Epub 2019 Apr 12 PubMed., In diet-induced obesity in these mice, NT-0796 caused weight loss as potently as did the GLP1 inhibitor semaglutide, and improved markers of cardiovascular risk (Thornton et al., 2024)., Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716., Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123688. Epub 2023 Mar 22 PubMed., Ortiz GU, de Freitas EC. Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging. Ageing Res Rev. 2024 Dec;102:102582. Epub 2024 Nov 14 PubMed., Zhang Y, Tang C, He Y, Zhang Y, Li Q, Zhang T, Zhao B, Tong A, Zhong Q, Zhong Z. Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models..